http://www.bing.com/news/search?q=ucb&setmkt=en-US&FORM=BNFD&format=rssSearch resultshttp://www.bing.com/rsslogo.gifhttp://www.bing.com/news/search?q=ucb&setmkt=en-US&FORM=BNFD&format=rssCopyright \xc2\xa9 2026 Microsoft. All rights reserved. These XML results may not be used, reproduced or transmitted in any manner or for any purpose other than rendering Bing results within an RSS aggregator for your personal, non-commercial use. Any other use of these results requires express written permission from Microsoft Corporation. By accessing this web page or using these results in any manner whatsoever, you agree to be bound by the foregoing restrictions.http://www.bing.com/news/apiclick.aspx?ref=FexRss&aid=&tid=6a1307573a2c4850a94c7f80b48656da&url=https%3a%2f%2ffinance.yahoo.com%2fsectors%2fhealthcare%2farticles%2fucb-acquires-candid-therapeutics-2-131450386.html&c=12524414531564740083&mkt=en-usThe Belgian pharma company is paying $2 billion upfront for Candid's pipeline of T-cell engagers targeting autoimmune diseases ...Mon, 04 May 2026 07:37:00 GMTYahoo Financehttp://www.bing.com/th?id=ONUT.HNzv2rRwpelhMc66jQLZew&pid=Newsw={0}&h={1}&c=141200675http://www.bing.com/news/apiclick.aspx?ref=FexRss&aid=&tid=6a1307573a2c4850a94c7f80b48656da&url=https%3a%2f%2fwww.biospace.com%2fdrug-development%2fabbvies-new-immunology-standard-bearer-skyrizi-kneels-to-ucbs-bimzelx-in-psoriatic-arthritis&c=534426464445410309&mkt=en-usUCB’s Bimzelx elicited significantly stronger joint relief at 16 weeks than AbbVie’s Skyrizi in a Phase 3 head-to-head study of psoriatic arthritis.Wed, 20 May 2026 04:50:00 GMTBioSpacehttp://www.bing.com/th?id=ONUT.0buWThBu_IU_CILaWcabeQ&pid=Newsw={0}&h={1}&c=141440810http://www.bing.com/news/apiclick.aspx?ref=FexRss&aid=&tid=6a1307573a2c4850a94c7f80b48656da&url=https%3a%2f%2fwww.fiercepharma.com%2fpharma%2fucb-presents-data-bimzelxs-head-head-win-over-abbvies-skyrizi&c=9768446896980413857&mkt=en-usTwo months after UCB revealed the success of Bimzelx in a head-to-head trial against AbbVie’s Skyrizi in patients with psoriatic arthritis (PsA), the Belgian drugmaker has unveiled the detailed ...Tue, 19 May 2026 04:27:00 GMTFiercePharmahttp://www.bing.com/news/apiclick.aspx?ref=FexRss&aid=&tid=6a1307573a2c4850a94c7f80b48656da&url=https%3a%2f%2fwww.fiercepharma.com%2fpharma%2fucbs-bimekizumab-remains-fda-limbo-agency-closes-inspection&c=12700135912190891997&mkt=en-usAfter a manufacturing-related complete response letter held up the U.S. launch of UCB’s psoriasis med bimekizumab last May, the FDA has officially closed out its inspection of the company's plant in ...Wed, 20 Sep 2023 05:59:00 GMTFiercePharmahttp://www.bing.com/news/apiclick.aspx?ref=FexRss&aid=&tid=6a1307573a2c4850a94c7f80b48656da&url=https%3a%2f%2fseekingalpha.com%2fnews%2f4594902-ucb-bimzelx-beat-abbvies-skyrizi-psoriatic-arthritis&c=3338827651268432810&mkt=en-usAbbVie (ABBV) stock is in focus as UCB's Bimzelx beats the company's immunology blockbuster Skyrizi in head-to-head trial for psoriatic arthritis. Read more here.Tue, 19 May 2026 06:52:00 GMTSeeking Alphahttp://www.bing.com/th?id=ONUT.RKi9bbY87rO9BFgj4q6uJg&pid=Newsw={0}&h={1}&c=14630420http://www.bing.com/news/apiclick.aspx?ref=FexRss&aid=&tid=6a1307573a2c4850a94c7f80b48656da&url=https%3a%2f%2fwww.msn.com%2fen-us%2fhealth%2fother%2fucb-doubles-down-on-tces-with-2-2bn-candid-buyout%2far-AA22ssU9&c=1054384520293616024&mkt=en-usThis acquisition marks UCB’s second foray into the TCE space – closely following a blockbuster licensing deal with TCE specialist, Antengene.Tue, 05 May 2026 04:12:54 GMTPharmaceutical Technology on MSNhttp://www.bing.com/th?id=ONUT.b2XhEePozDXyyCknVpPyVg&pid=Newsw={0}&h={1}&c=1425601920